Company intelligence / Profile preview

Pollogen

Tel Aviv, Tel Aviv District, Israelpollogen.com ↗

Ownership: Private
Development stage: Other

Overview

Pollogen’s devices—including TriPollar, OxyGeneo, VoluDerm, and others—are clinically proven for non-invasive or minimally invasive skin rejuvenation. Their products have received regulatory clearances such as FDA approval for home-use devices like TriPollar Stop. The company’s solutions are used by professionals in over sixty countries and have broad market acceptance in both clinical/aesthetic practices and consumer/home settings.

Therapeutic areas: DermatologyOther
Modalities: Device (Radio-frequency based)Device (Ultrasound-based)Device (Microneedling/fractional RF)Device (Oxygenation-based facial therapy)Non-pharmacological therapy
Industry: Therapeutic Medical Devices

Partnerships

No major pharma partnerships reported; distribution partners globally for medical aesthetics market.

Beyond the preview

Go deeper on Pollogen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pollogen.

Explore the full profile